Leukemia & Lymphoma
Long-term follow-up results from the FoRT study shows that the optimal RT dose for patients with indolent NHL is _________.
Fill in the Blank: Long-term follow-up results from the FoRT study show that the optimal radiotherapy dose to treat patients with indolent non-Hodgkin lymphoma is ___ Gy in ___ fractions, according…
Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN…
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.